CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation

August 21, 2019 admin Healthcare, Investor Presentations Comments Off on CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation

CytoDyn, Inc. (OTC: CYDY)

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Next Super Stock investor conference presentation 8/15/2019




Related Articles

Healthcare

CytoDyn (OTC: CYDY) Executes Exclusive Worldwide Licensing Agreement with IncellDX for PA-14 and PRO 140 for Diagnostic Testing Purposes

July 29, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Executes Exclusive Worldwide Licensing Agreement with IncellDX for PA-14 and PRO 140 for Diagnostic Testing Purposes

Agreement represents a revenue opportunity as a diagnostic test for receptor occupancy and the existence of CCR5 on cancer tissue and in HIV VANCOUVER, Washington, Jul 26, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the […]

Healthcare

CytoDyn (OTC: CYDY) Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA

February 14, 2020 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA

VANCOUVER, Washington, Feb. 14, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today continued positive […]